RecruitingNot applicableNCT06775457
Genome Analysis of Human Endogenous Retroviruses (HERVs)(COVID19)
Studying Kawasaki disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Principal Investigator
- Marianna Fabi, MDIRCCS Azienda Ospedaliero-Universitaria di Bologna
- Intervention
- sample collection(other)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (5)
- Ospedale Ramazzini di Carpi, Azienda USL di Modena UO Pediatria, Carpi, Modena, Italy
- IRCCS Azienda Ospedaliero - Universitaria di Bologna, U.O. Pediatria d'Urgenza, Pronto Soccorso e Osservazione Breve ed Intensiva, Bologna, Italy
- Azienda Ospedaliera-Universitaria di Modena, Modena, Italy
- IRCCS Ospedale Pediatrico Bambino Gesù UOC Pediatria Generale, Roma, Italy
- Ospedale Regina Margherita, Torino, UO Reumatologia Pediatrica, Torino, Italy
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06775457 on ClinicalTrials.govOther trials for Kawasaki disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05643651Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki DiseaseChildren's Hospital of Fudan University
- RECRUITINGNANCT07291245Kawasaki MATCH TrialUniversity of California, San Diego
- ENROLLING BY INVITATIONNCT06641843Magnetic Resonance Myocardial Stress Perfusion in Pediatric Patients with Cardiovascular DiseaseWest China Second University Hospital
- RECRUITINGPHASE4NCT06978439Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki DiseaseChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT04656184A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG TreatmentAssistance Publique - Hôpitaux de Paris
- ENROLLING BY INVITATIONNCT06641817The Value of Cardiovascular Imaging in Kawasaki DiseaseWest China Second University Hospital
- RECRUITINGNCT06993636Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 YearsChildren's Hospital of Fudan University
- RECRUITINGNCT06305611European and North Indian Cohort of KaWasaki dIseaseMeyer Children's Hospital IRCCS